Privatizing Biomedical Research - A 'Third Way'

Nature Biotechnology, Vol. 26, No. 1, pp. 31-36, 2008

6 Pages Posted: 15 Nov 2012 Last revised: 24 Feb 2014

See all articles by Ron Bouchard

Ron Bouchard

University of Manitoba - Faculty of Law (deceased)

Trudo Lemmens

University of Toronto - Faculty of Law

Abstract

The allocation of risks and benefits of publicly sponsored biomedical research is becoming increasingly skewed toward for-profit entities and against the public interest. A legitimate solution to this imbalance would be to levy compulsory government royalty fees on commercial products made possible by public efforts.

Keywords: technology, innovation, commercialization, medical research

Suggested Citation

Bouchard, Ron and Lemmens, Trudo, Privatizing Biomedical Research - A 'Third Way'. Nature Biotechnology, Vol. 26, No. 1, pp. 31-36, 2008, Available at SSRN: https://ssrn.com/abstract=984518

Ron Bouchard

University of Manitoba - Faculty of Law (deceased)

Trudo Lemmens (Contact Author)

University of Toronto - Faculty of Law ( email )

78 and 84 Queen's Park
Toronto, Ontario M5S 2C5
Canada

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
87
Abstract Views
821
rank
344,564
PlumX Metrics